Myocarditis after BNT162b2 mRNA Vaccine against Covid-19

 

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel

List of authors.

• Dror Mevorach, M.D., 
• Emilia Anis, M.D., M.P.H., 
• Noa Cedar, M.P.H., 
• Michal Bromberg, M.D., M.P.H., 
• Eric J. Haas, M.D., M.S.C.E., 
• Eyal Nadir, M.D., 
• Sharon Olsha-Castell, M.D., 
• Dana Arad, R.N., M.S.N., 
• Tal Hasin, M.D., 
• Nir Levi, M.D., 
• Rabea Asleh, M.D., Ph.D., 
• Offer Amir, M.D., 

• BACKGROUND

  Approximately 5.1 million Israelis had been fully immunized against coronavirus disease 2019 (Covid-19) after receiving two doses of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) by May 31, 2021. After early reports of myocarditis during adverse events monitoring, the Israeli Ministry of Health initiated active surveillance.

• ......

• CONCLUSIONS

  The incidence of myocarditis, although low, increased after the receipt of the BNT162b2 vaccine, particularly after the second dose among young male recipients.

On the basis of data from an Israeli national database, the incidence of myocarditis after two doses of the BNT162b2 mRNA vaccine was low but higher than the incidence among unvaccinated persons and among historical controls. The risk of myocarditis was driven primarily by the increased incidence after the second dose of vaccine and in young male recipients.

• Continue here:

• https://www.nejm.org/doi/10.1056/NEJMoa2109730?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed